Plans call for several hundred local jobs, 36 workstations and the capability to make $375 million to $750 million worth of Provenge a year, said Greg Schiffman, the drug maker's chief financial officer, in an interview last year. Provenge is designed for men whose prostate cancer has spread and is resistant to traditional forms of treatment. The drug trains the body's immune system to fight prostate cancer and is called a vaccine, although it treats cancer rather than prevents it. ReVision Leader John Kilcoyne is the new chief executive and president of ReVision Optics Inc., a Lake Forest eye device maker. He succeeds J. Randy Alexander, who assumes the chairman's role.